Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lauren J Akers

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Pediatric Hematology/Oncology|December 12, 2018
Response to Pazopanib in Patients With Relapsed OsteosarcomaKunal R Elete, Karen H Albritton, Lauren J Akers, et al.
Leukemia Research|February 15, 2011
Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycinLauren J Akers, Wendy Fang, Alejandro G Levy, et al.
Lymphatic Research and Biology|August 26, 2021
Multidisciplinary Multiagent Treatment of Complex Lymphatic Anomalies with Severe Bone Disease: A Single-Site ExperienceMegan D Anthony, Aubrey Swilling, Zahra M Jiwani, et al.
Investigational New Drugs|October 5, 2010
The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastomaAlejandro G Levy, Peter E Zage, Lauren J Akers, et al.
The Journal of Experimental Medicine|January 30, 2013
Notch activation inhibits AML growth and survival: a potential therapeutic approachSankaranarayanan Kannan, Robert M Sutphin, Mandy G Hall, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Pediatric Hematology/Oncology|December 12, 2018
Response to Pazopanib in Patients With Relapsed OsteosarcomaKunal R Elete, Karen H Albritton, Lauren J Akers, et al.
Leukemia Research|February 15, 2011
Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycinLauren J Akers, Wendy Fang, Alejandro G Levy, et al.
Lymphatic Research and Biology|August 26, 2021
Multidisciplinary Multiagent Treatment of Complex Lymphatic Anomalies with Severe Bone Disease: A Single-Site ExperienceMegan D Anthony, Aubrey Swilling, Zahra M Jiwani, et al.
Investigational New Drugs|October 5, 2010
The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastomaAlejandro G Levy, Peter E Zage, Lauren J Akers, et al.
The Journal of Experimental Medicine|January 30, 2013
Notch activation inhibits AML growth and survival: a potential therapeutic approachSankaranarayanan Kannan, Robert M Sutphin, Mandy G Hall, et al.
Pageof 1